Cell News and Research

RSS

Castle Biosciences reports study results from DecisionDx-EC multi-analyte test for esophageal cancer

Castle Biosciences Inc. today announced study results from its proprietary multi-analyte test DecisionDx-EC, which is designed to determine which patients with esophageal cancer are likely to respond or not respond to standard pre-surgical chemoradiation therapy.

31 May 2014

Amgen presents extended analysis of PEAK study data at ASCO

Amgen today announced results from the Phase 2 PEAK study that reinforce the improved overall survival (OS) benefit of panitumumab (Vectibix®) when used in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, compared to bevacizumab (Avastin) plus FOLFOX as first-line treatment in patients with wild-type RAS metastatic colorectal cancer (mCRC).

31 May 2014

New cancer panel holds promise in detection of previously undetected viral, cancer mutations

Researchers from Sanford Health and Chronix Biomedical today announced that results from a pilot study demonstrating the utility of a new cancer panel to detect previously undetected viral and cancer mutations are to be reported in a poster presentation titled "Detection of novel HPV mutations and chromosomal number imbalance (CNI) in oropharyngeal and laryngeal cancer using next-generation sequencing (NGS)" (Abstract #6072) at the American Society of Clinical Oncology Annual Meeting (ASCO 2014) being held from May 30 through June 3, 2014 in Chicago.

31 May 2014

Experts from ProfNet network available to discuss timely issues in coverage area

Below are experts from the ProfNet network that are available to discuss timely issues in your coverage area. If you are interested in interviewing any of the experts, please contact them via the contact information at the end of the listing.

31 May 2014

New data highlights molecular profiling in guiding treatment of patients with gynecologic malignancies

Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of precision medicine, announced today the presentation of clinical data from studies demonstrating the potential utility of comprehensive molecular profiling in guiding treatment of patients with gynecologic malignancies, including breast cancers and ovarian cancer.

31 May 2014

$ASCO: DelMar presents interim data from VAL-083 clinical trial in refractory GBM$

ASCO: DelMar presents interim data from VAL-083 clinical trial in refractory GBM

DelMar Pharmaceuticals, Inc. announced the presentation of interim clinical data from the company's ongoing clinical trial with VAL-083 in refractory glioblastoma multiforme (GBM) during the Central Nervous System Tumor Session at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held at the McCormick Place Convention Center in Chicago.

31 May 2014

ASCO honors St. Jude researcher with 2014 Pediatric Oncology Award

The American Society of Clinical Oncology (ASCO) has named Leslie L. Robison, Ph.D., of St. Jude Children's Research Hospital the recipient of the 2014 Pediatric Oncology Award for his contributions to the field of childhood cancer survivorship research.

31 May 2014

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

Boehringer Ingelheim today announced that new data will be presented from 7 abstracts for Gilotrif (afatinib) and investigational compounds, including nintedanib and BI 836845, from its oncology pipeline at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, on May 30 – June 3, 2014.

31 May 2014

CIRM grants $5.6 million to develop HIV/AIDS therapeutic using Sangamo's ZFN genome-editing technology

Sangamo BioSciences, Inc. announced that the California Institute for Regenerative Medicine (CIRM) has granted a $5.6 million Strategic Partnership Award to fund clinical studies at City of Hope to develop a potentially curative ZFP Therapeutic for HIV/AIDS based on the application of Sangamo's zinc finger nuclease (ZFN) genome-editing technology in hematopoietic stem/progenitor cells (HSPCs).

31 May 2014

Morphogenesis announces publication of new book, Cancer Vaccines: Methods and Protocols

Drs. Michael J.P. Lawman and Patricia D. Lawman, founders of the Tampa-based biotech firm Morphogenesis Inc., announce the publication of "Cancer Vaccines: Methods and Protocols," the most definitive work to date in the promising field of cancer vaccines.

31 May 2014

Protein complex structure that plays an important role in regulating circadian rhythm identified

Structural biologists have made important progress towards better understanding the functioning of the circadian clock. The circadian or inner clock coordinates the sleep-wake rhythm and many other body processes that regulate, for example, metabolism, blood pressure, and the immune system.

31 May 2014

Astellas seeks marketing approval for Flublok recombinant influenza vaccine in Japan

Protein Sciences Corporation announced today that Astellas Pharma has submitted an application for marketing approval of recombinant influenza HA vaccine ASP7374 (marketed as Flublok® in the United States by Protein Sciences) to the Ministry of Health, Labour and Welfare in Japan for the prevention of influenza.

31 May 2014

Agena Bioscience expands ultrasensitive somatic mutation detection technology

Agena Bioscience, Inc., which recently acquired the Bioscience business of Sequenom, Inc., today announced expansion of the UltraSEEK™ technology, the first ultrasensitive somatic mutation detection technology for high-throughput and definitive interrogation of rare mutations that occur at less than 1% abundance in matched tissue, circulating plasma, and tumor samples.

31 May 2014

Patients with AIDS-related lymphomas may face increased risk of CNSi

Patients with AIDS-related lymphomas (ARL) may face an increased risk of central nervous system involvement (CNSi) compared to other lymphomas. The effect of CNSi on survival outcomes, however, hasn't been thoroughly examined until now.

31 May 2014

Deciphera initiates altiratinib MET/TIE2/VEGFR/TRK kinase inhibitor Phase 1 trial for solid tumors

Deciphera Pharmaceuticals, a clinical stage biotechnology company focused on improved kinase inhibitor treatments for cancer, today announced the initiation of a Phase 1 clinical trial of its MET/TIE2/VEGFR2/TRK inhibitor altiratinib (DCC-2701).

31 May 2014

Genetic changes can predict which patient will benefit from chemotherapy before bladder cancer surgery

Three genetic changes can predict whether a patient will benefit from chemotherapy before surgery to remove bladder cancer, according to new findings presented by Fox Chase Cancer Center researchers during the 50th Annual Meeting of the American Society of Clinical Oncology.

31 May 2014

DNA-binding fluorescent dyes evaluate cytotoxicity in real-time during screening

High throughput screening of compounds in live cells is a powerful approach for discovering new drugs, but the potential for cell toxicity must be considered.

31 May 2014

Scientists explain how green tea may work to reduce risk of cancer

Green tea and its extracts have been widely touted as potential treatments for cancer, as well as several other diseases.

31 May 2014

Inovio Pharmaceuticals’ reverse stock split to become effective on June 5, 2014

Inovio Pharmaceuticals, Inc. today announced that its previously announced 1-for-4 reverse stock split shall become effective at 5 P.M., Thursday, June 5, 2014, and trading of the Company's common stock on a post-reverse split basis shall commence on Friday, June 6, 2014.

30 May 2014

EKF, GILUPI report data on circulating tumour cell DNA enrichment, mutation detection

EKF and GILUPI, announce results from collaborative work using GILUPI CellCollector and EKF Molecular’s PointMan DNA Enrichment technology.

From EKF Diagnostics 30 May 2014

Cell News and Research

Castle Biosciences reports study results from DecisionDx-EC multi-analyte test for esophageal cancer

Amgen presents extended analysis of PEAK study data at ASCO

New cancer panel holds promise in detection of previously undetected viral, cancer mutations

Experts from ProfNet network available to discuss timely issues in coverage area

New data highlights molecular profiling in guiding treatment of patients with gynecologic malignancies

ASCO: DelMar presents interim data from VAL-083 clinical trial in refractory GBM

ASCO honors St. Jude researcher with 2014 Pediatric Oncology Award

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

CIRM grants $5.6 million to develop HIV/AIDS therapeutic using Sangamo's ZFN genome-editing technology

Morphogenesis announces publication of new book, Cancer Vaccines: Methods and Protocols

Protein complex structure that plays an important role in regulating circadian rhythm identified

Astellas seeks marketing approval for Flublok recombinant influenza vaccine in Japan

Agena Bioscience expands ultrasensitive somatic mutation detection technology

Patients with AIDS-related lymphomas may face increased risk of CNSi

Deciphera initiates altiratinib MET/TIE2/VEGFR/TRK kinase inhibitor Phase 1 trial for solid tumors

Genetic changes can predict which patient will benefit from chemotherapy before bladder cancer surgery

DNA-binding fluorescent dyes evaluate cytotoxicity in real-time during screening

Scientists explain how green tea may work to reduce risk of cancer

Inovio Pharmaceuticals’ reverse stock split to become effective on June 5, 2014

EKF, GILUPI report data on circulating tumour cell DNA enrichment, mutation detection

Industry focus eBook - Cell and gene therapy (2nd edition) eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring